A. Company Profile

Oxigene (NASDAQ:OXGN) is the world leader in vascular targeting, a revolutionary approach to the treatment of cancers

B. Products

Product Pipelines

Product

Indication

Clinical Status

Zybrestat (Combretastatin -A4 phosphate/

CA4P)

Various tumors

Phase I-III

Oxi4503

(Combretastatin -A4 phosphate/

CA4P)

Various tumors

Phase I

1. Zybrestat

Zybrestat, Combretastatin-A4 phosphate, is a synthetic compound and acts as a vascular targeting agent (VTA). It has been shown to attack the blood vessels of solid tumors and may have applications in other diseases characterized by neo-vasculature. It was originally derived from the root bark of the Combretum caffrum tree, also known as the Cape Bushwillow. VTA attacks the vasculature within the tumor itself, reducing blood flow to deprive the tumor of oxygen and nutrients, causing tumor cell death. Unlike anti-angiogenesis drugs, which attempt to prevent the formation of new tumor blood vessels from developing, the VTA Combretastatin A4 Prodrug starves existing solid tumors by depriving them of the blood flow that feeds the tumor, causing tumor cell death.

2. Oxi4503

OXi4503 (combretastatin A1 di-phosphate / CA1P) is a unique and highly potent, dual-mechanism vascular disrupting agent (VDA). Like its structural analog, ZYBRESTAT, OXi4503 blocks and destroys tumor vasculature, resulting in extensive tumor cell death and necrosis. In addition, however, preclinical data demonstrates that OXi4503 is metabolized by oxidative enzymes (e.g., tyrosinase and peroxidases), which are elevated in many solid tumors and tumor infiltrates, to an orthoquinone chemical species that has direct cytotoxic effects on tumor cells.